Sumitomo Dainippon Pharma Co. Ltd., of Osaka, Japan, is among five partners investigating renal regenerative medicine, in a group that also includes: Bios Co. Ltd., of Tokyo; Pormedtec Co. Ltd., of Kawasaki City, Japan; the Jikei University School of Medicine in Tokyo; and Meiji University in Tokyo.